卡维地洛与缬沙坦联用治疗慢性心力衰竭临床研究

The clinical study of carvedilol combined with valsartan on chronic heart failure

目的观察并探讨卡维地洛与缬沙坦联用治疗慢性心力衰竭临床效果及安全性。方法选取我院2007年5月至2011年10月收治慢性心力衰竭患者197例,随机分为两组,其中对照组99例,在常规抗心衰治疗基础上,采用缬沙坦口服治疗;实验组98例,在对照组治疗基础上,加用卡维地洛口服治疗;疗程均为6个月,治疗结束后评价临床效果及不良反应发生情况。结果实验组患者治疗总有效率明显高于对照组,组间比较差异有统计学意义(P<0.05);实验组患者血压及心率改善程度均明显优于对照组患者,组间比较差异有统计学意义(P<0.05);实验组患者治疗后LVEF、LVD、LVS及SV等超声心动图指标改善程度均明显优于对照组患者,组间比较差异亦有统计学意义(P<0.05);同时两组患者不良反应发生率组间比较差异无统计学意义(P>0.05)。结论卡维地洛联合缬沙坦治疗慢性心力衰竭临床效果确切,能够有效改善患者心脏功能,同时无严重不良反应,可在临床加以推广使用。

Objective To observe and investigate therapeutic effect and security of carvedilol treatment combined with valsartan on chronic heart failure. Methods 197 patients with chronic heart failure were chose in the period from May 2007 to October 2011 in our hospital and randomly divided into two groups including control group （99 patients） with valsartan treatment and experimental group （98 patients） with carvedilol treatment combined with valsartan both for 6 months, and after treatment the therapeutic effects and adverse effects were assessed. Results The total effective rate of experimental group were significantly higher than control group （ P 〈 0.05 ）. The improvement degree of blood pressure, heart rate, LVEF, LVD, LVS, and SV of experimental group were also significantly better than control group（ P 〈 0.05 ）. There was no significant difference in the incidence of adverse effects between control group and experimental group （ P 〉 0. 05 ）. Conclusion The carvedilol treatment combined with valsartan on chronic heart failure possess excellent clinical effect, can effectively improve cardiac function, have no serious adverse effects, and is worthy of clinical application.